Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

"The patient is speaking": discovering the patient voice in ophthalmology.

Dean S, Mathers JM, Calvert M, Kyte DG, Conroy D, Folkard A, Southworth S, Murray PI, Denniston AK.

Br J Ophthalmol. 2017 Jun;101(6):700-708. doi: 10.1136/bjophthalmol-2016-309955. Epub 2017 Apr 28. Review.

3.

Schizophrenia Outpatient Health Outcomes study: twelve-month findings.

Novick D, Ascher-Svanum H, Haro JM, Bertsch J, Takahashi M.

Pragmat Obs Res. 2012 Jun 6;3:27-40. eCollection 2012.

4.

Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis.

Denniston AK, Holland GN, Kidess A, Nussenblatt RB, Okada AA, Rosenbaum JT, Dick AD.

Orphanet J Rare Dis. 2015 Aug 19;10:97. doi: 10.1186/s13023-015-0318-6. Review.

5.

Outcomes in Cochrane systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability.

Saldanha IJ, Dickersin K, Wang X, Li T.

PLoS One. 2014 Oct 16;9(10):e109400. doi: 10.1371/journal.pone.0109400. eCollection 2014. Review.

6.

Poor adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacological treatments (NPT): a cross-sectional study.

Nagendran M, Harding D, Teo W, Camm C, Maruthappu M, McCulloch P, Hopewell S.

BMJ Open. 2013 Dec 18;3(12):e003898. doi: 10.1136/bmjopen-2013-003898.

7.

How psychiatry journals support the unbiased translation of clinical research. A cross-sectional study of editorial policies.

Knüppel H, Metz C, Meerpohl JJ, Strech D.

PLoS One. 2013 Oct 16;8(10):e75995. doi: 10.1371/journal.pone.0075995. eCollection 2013.

8.

Fluphenazine (oral) versus placebo for schizophrenia.

Matar HE, Almerie MQ, Sampson S.

Cochrane Database Syst Rev. 2013 Jul 17;(7):CD006352. doi: 10.1002/14651858.CD006352.pub2. Review.

9.

Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers.

Teferra S, Hanlon C, Beyero T, Jacobsson L, Shibre T.

BMC Psychiatry. 2013 Jun 17;13:168. doi: 10.1186/1471-244X-13-168.

10.

Where Does Evidence from New Trials for Schizophrenia Fit with the Existing Evidence: A Case of the Emperor's New Clothes?

Jayaram M, Rattehalli RD, Adams CE.

Schizophr Res Treatment. 2012;2012:625738. doi: 10.1155/2012/625738. Epub 2012 Apr 8.

11.

External validity of studies on aggressive behavior in patients with schizophrenia: systematic review.

Steinert T, Hamann K.

Clin Pract Epidemiol Ment Health. 2012;8:74-80. doi: 10.2174/1745017901208010074. Epub 2012 Aug 23.

12.

Schizophrenia trials conducted in African countries: a drop of evidence in the ocean of morbidity?

Purgato M, Adams C, Barbui C.

Int J Ment Health Syst. 2012 Jul 6;6(1):9.

13.

Forty-five years of schizophrenia trials in Italy: a survey.

Purgato M, Adams C, Barbui C.

Trials. 2012 Apr 12;13:35. doi: 10.1186/1745-6215-13-35.

14.

Content and quality of 10,000 controlled trials in schizophrenia over 60 years.

Miyar J, Adams CE.

Schizophr Bull. 2013 Jan;39(1):226-9. doi: 10.1093/schbul/sbr140. Epub 2012 Jan 30.

15.

Using the needs of WHO to prioritise Cochrane reviews: The case of antipsychotic drugs.

Purgato M, Barbui C, Adams CE.

Int J Ment Health Syst. 2011 Sep 24;5:25. doi: 10.1186/1752-4458-5-25.

16.

Mind, brain and psychotherapy.

Sheth HC.

Indian J Psychol Med. 2009 Jan;31(1):11-5. doi: 10.4103/0253-7176.53309.

17.
18.

The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial.

Melau M, Jeppesen P, Thorup A, Bertelsen M, Petersen L, Gluud C, Krarup G, Nordentoft M.

Trials. 2011 Mar 10;12:72. doi: 10.1186/1745-6215-12-72.

19.

Family intervention for schizophrenia.

Pharoah F, Mari J, Rathbone J, Wong W.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD000088. doi: 10.1002/14651858.CD000088.pub2. Review.

20.

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG.

BMJ. 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869. No abstract available.

Supplemental Content

Support Center